Function Health Snaps Up $450M as EU AI Act Bites

Inside Function Health's Medical Intelligence Model

Function Health's business model represents the cutting edge of what is often termed 'precision medicine,' yet it operates in a grey area that regulators are now actively scrutinising.

The company's proprietary Medical Intelligence Lab processes vast amounts of user data to generate personalised risk profiles, a service that blends wellness with clinical diagnostics.

For an annual fee of $365, patients receive a deep dive into their biochemistry, accessing metrics that were previously the domain of specialised clinics.

Furthermore, the company offers full-body MRI and CT imaging for under $1,000 through a network of partner centres, a pricing model that democratises access to high-end radiology.

This approach relies heavily on artificial intelligence to interpret the resulting flood of data.

However, under the new EU framework, AI systems used in healthcare are classified as 'high-risk.'

This designation triggers a rigorous set of requirements, including strict data governance, transparency obligations, and human oversight measures.

Function Health's model, if transplanted to Europe, would immediately trigger these obligations.

The company's use of AI to analyse biomarkers and imaging results would require a CE marking specifically for the software as a medical device (SaMD).

Moreover, the 'black box' nature of some AI analytics—where the decision-making process is opaque—is directly targeted by the AI Act's transparency provisions.

European regulators demand that patients understand not just *what* their risk is, but *how* the AI arrived at that conclusion.

This poses a significant challenge for algorithms that rely on deep learning, where the internal logic is often not even fully understood by their developers.

• Full-body MRI scans are offered for under $1,000.
• AI systems in healthcare are classified as 'high-risk' in the EU.
• The Medical Intelligence Lab processes data into risk profiles.

The aggressive pricing strategy of Function Health suggests a bet on volume.

By making comprehensive diagnostics affordable, the company aims to shift healthcare from reactive treatment to proactive prevention.

Yet, in Europe, prevention is often funded by public health systems that are notoriously conservative about adopting new technologies without robust cost-effectiveness data.

The $450 million war chest will undoubtedly be used to refine these algorithms and, crucially, to fund the legal teams needed to navigate the Brussels bureaucracy.

Why CE Marking Is Only the First Step

A central theme of the recent regulatory discussions is the misconception that obtaining a CE mark guarantees commercial success in Europe.

While the CE mark certifies that a medical device meets safety and performance requirements, it does not ensure that national health systems will pay for it.

This distinction is the 'reimbursement gap' that sinks many promising MedTech startups.

The 'Big Law Redefined' podcast emphasises that companies must design their clinical evidence strategies with reimbursement in mind from day one.

In countries like Germany, France, and the United Kingdom, the process for getting a digital health tool reimbursed by statutory payers is distinct and often fragmented.

For instance, Germany's DiGA (Digital Health Applications) fast-track process requires evidence of patient-relevant benefits, while the UK's National Institute for Health and Care Excellence (NICE) conducts rigorous health technology assessments.

A recent analysis from the European Hematology Association (EHA) 2026 congress highlighted the difficulty of 'translating evidence into impact.'

Experts noted that generating clinical trial data is expensive and time-consuming, yet it is the currency required to unlock public funding.

Without this data, even a legally compliant device remains a private-pay product, limiting its market potential to a wealthy few rather than the general population.

• CE marking certifies safety but not reimbursement eligibility.
• Germany's DiGA scheme demands proof of patient benefits.
• NICE assessments are required for NHS adoption in the UK.

The financial implications are profound.

A company might spend millions securing a CE mark, only to find that no hospital budget exists to purchase their product.

Legal experts now advise that reimbursement strategies should be drafted in tandem with technical development.

This involves early engagement with health technology assessment (HTA) bodies to understand exactly what kind of data they will require years down the line.

It is a shift from a 'compliance-first' mindset to a 'value-demonstration' mindset.

For a company like Function Health, proving that their $365 annual subscription prevents expensive hospitalisations later would be the key to unlocking European public funds.

However, generating that longitudinal data takes time—time that startups burning cash do not always have.

The AI Office's €15 Million Enforcement Stick

The activation of the European Commission's AI Office marks a new era of digital enforcement in Europe.

This body is not merely a guideline generator; it possesses the authority to investigate non-compliance and levy fines that can cripple even the largest multinational corporations.

The penalty structure—3% of global annual turnover or €15 million, whichever is higher—is designed to be punitive enough to force compliance.

For a tech giant, 3% of global turnover represents billions of euros.

For a smaller Series B startup, a €15 million fine could be an existential threat.

The legislation applies extraterritorially, meaning that any company outside the EU whose AI system is used by people within the EU falls under its jurisdiction.

This effectively forces American and Asian companies to adhere to Brussels' standards if they wish to access the 450 million consumers in the single market.

The 'Big Law Redefined' series warns that the 'Brussels Effect' in digital health will be profound.

We have already seen this with data protection under GDPR; the AI Act is set to replicate that dynamic for algorithmic governance.

The Act specifically targets 'medical devices' as a high-risk category